The United States Trade Representative (USTR) disclosed the '2025 National Trade Estimate (NTE) Report on Foreign Trade Barriers,' while the Ministry of Trade, Industry and Energy expressed that it will continue practical consultations with the U.S. regarding non-tariff measures.
On the 1st, the ministry noted, 'The U.S. is expected to impose mutual tariffs, and there is a heightened interest in non-tariff measures,' adding, 'We will closely consult with relevant authorities and stakeholders on the issues raised in the NTE report and prepare a response plan by thoroughly analyzing the content.'
It further explained, 'We plan to negotiate through practical channels with the U.S., the Korea-U.S. Free Trade Agreement (FTA) Implementation Committee, and working groups, continuously explaining our efforts regarding non-tariff measures and ensuring that our positions on key issues such as mutual tariffs are reflected as much as possible.'
Earlier in February, when the USTR publicly gathered opinions, the ministry submitted its views on the content submitted by U.S. stakeholders, detailing its position through in-person consultations. Furthermore, during a recent visit by ministers, it actively stated, 'We are making various efforts to improve the business environment for foreign investors and to facilitate trade. Korea's non-tariff barriers are by no means at a high level compared to other major trading countries.'
Meanwhile, the USTR identified 21 non-tariff measures of Korea in the NTE report released the previous day. This is a slight increase compared to last year, but less than the level before 2023 (around 40).
The USTR mentioned, 'Under the Korea-U.S. FTA, tariffs on most products have been eliminated, and we are regularly discussing bilateral issues through the implementation committee and working groups,' while also repeatedly highlighting the non-tariff measures that have been raised as issues. The non-tariff measures of Korea identified in the report included digital trade, government procurement, agricultural market access, services, and drug pricing.